MIR, offers research to support universities and pharmaceutical industries, according to the high quality standards dictated by regulations UNI EN ISO 9001:2015.
It develops for third parties, early in vitro and in vivo screening, ranging from small molecules to biological products and preclinical studies aimed to Investigational New Drug (IND) application. The Protein Factory Unit ”from gene to protein” has capability to produce proteins from micro-to-grams scale and set up methods for large scale production.
MIR success arises from its philosophy oriented to Customer’s problem solving and offering a wide, technologically advanced, range of research services.
It combines the commitment to results with high scientific standards through the application of validated Standard Operative Procedure (SOP).
In parallel to the research activities for third parties, MIR has proprietary research project/products on new therapeutics for cancer and inflammation related diseases.